PUBLISHER: Persistence Market Research | PRODUCT CODE: 1568973
PUBLISHER: Persistence Market Research | PRODUCT CODE: 1568973
AI in Oncology Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031
Persistence Market Research has recently released a comprehensive report on the global AI in Oncology Market, providing an in-depth analysis of key market dynamics, including drivers, trends, opportunities, and challenges. This detailed report sheds light on the market structure and growth potential over the forecast period.
Key Insights:
- AI in Oncology Market Size (2024E): US$1.7 billion
- Projected Market Value (2031F): US$10.1 billion
- Global Market Growth Rate (CAGR 2024 to 2031): 16.4%
AI in Oncology Market - Report Scope:
Artificial Intelligence (AI) has become a critical tool in revolutionizing various sectors, including pharmaceutical and biotechnology industries. The use of AI in oncology, in particular, has shown great promise, offering accelerated drug discovery, development, and improved cancer detection capabilities. The integration of AI in healthcare has enhanced treatment precision and patient care, creating more personalized approaches for oncology patients.
Market Growth Drivers:
Several key factors are propelling the growth of the global AI in Oncology Market. The increasing global burden of cancer is a significant driver, with cancer incidences rising rapidly worldwide. The growing demand for faster and more accurate diagnostic services, coupled with a shortage of experts in oncology, has led to a surge in the adoption of AI-powered solutions. These technologies are helping medical professionals process large volumes of data, streamline diagnostics, and make informed treatment decisions, contributing to enhanced patient outcomes. Additionally, the use of AI for early detection, cancer genomics, and biomarker assessments is expanding rapidly, helping healthcare professionals create targeted, personalized treatments. AI is also enabling breakthroughs in drug discovery, making it a key driver of innovation in cancer research.
Market Restraints:
Despite its tremendous growth potential, the AI in Oncology Market faces challenges. The complexity of cancer cases, requiring multi-disciplinary treatment approaches, often results in delays in diagnosis and care. This can be exacerbated by the varying manifestations of cancer in individuals. Additionally, data privacy and security concerns surrounding the use of AI technologies in healthcare remain significant, particularly due to the large amounts of sensitive patient data that are collected and processed. Moreover, ensuring AI technologies' seamless integration with existing healthcare infrastructure remains a challenge, requiring collaboration between healthcare institutions and AI developers.
Market Opportunities:
The global AI in Oncology Market presents substantial growth opportunities, particularly with the rising adoption of AI-driven cancer diagnostics. AI's ability to analyze medical imaging with higher accuracy than traditional methods is attracting attention, with applications such as mammography, CT scans, and tumor detection proving especially promising. AI's role in predicting cancer risk through genetic and medical imaging data analysis is also expanding, further driving market growth. Collaborations between AI developers and healthcare providers present another avenue for growth. These partnerships facilitate clinical validation, technology evaluation, and the deployment of AI solutions in real-world healthcare settings. Innovations in AI-powered cancer treatments, such as personalized chemotherapy regimens and optimized drug discovery, are expected to further fuel market expansion.
Competitive Intelligence and Business Strategy:
Leading players in the AI in Oncology Market, including companies such as Azra AI, IBM, Siemens Healthcare GmbH, GE Healthcare, NVIDIA Corporation, and PathAI, are heavily investing in research and development to strengthen their positions. These companies are focusing on collaborations with healthcare institutions to co-develop AI solutions that meet specific clinical needs. Additionally, regulatory approvals for AI-driven devices and applications in oncology, particularly in radiology, are accelerating the adoption of these technologies. Ensuring data security, regulatory compliance, and addressing privacy concerns will be key for these companies to maintain a competitive edge in the market.
Key Companies Profiled:
- Azra AI
- IBM
- Siemens Healthcare GmbH
- Intel Corporation
- GE Healthcare
- NVIDIA Corporation
- Digital Diagnostics Inc.
- ConcertAI
- Median Technologies
- PathAI
- Berg (BPGbio Inc.)
- CancerCenter.AI
- iCAD
- JLK Inspection
- Roche Diagnostics
- Zebra Medical Vision
- Illumina Inc.
- Envisionit DeepAI Ltd
AI in Oncology Market Segmentation:
By Component:
- Software Solutions
- Hardware
- Services
By Indication:
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Colorectal Cancer
- Brain Tumor
- Others
By Treatment:
- Chemotherapy
- Immunotherapy
- Radiotherapy
- Others
By End User:
- Hospitals
- Biopharmaceutical Companies
- Academic and Research Centers
- Others
By Region:
- North America
- Europe
- East Asia
- South Asia & Oceania
- Latin America
- Middle East and Africa
Table of Contents
1.Executive Summary
- 1.1.Global AI in Oncology Market Snapshot, 2024-2031
- 1.2.Market Opportunity Assessment, 2024-2031, US$ Mn
- 1.3.Key Market Trends
- 1.4.Future Market Projections
- 1.5.Premium Market Insights
- 1.6.Industry Developments and Key Market Events
- 1.7.PMR Analysis and Recommendations
2.Market Overview
- 2.1.Market Scope and Definition
- 2.2.Market Dynamics
- 2.2.1.Drivers
- 2.2.2.Restraints
- 2.2.3.Opportunity
- 2.2.4.Key Trends
- 2.3.Macro-Economic Factors
- 2.3.1.Global Sectorial Outlook
- 2.3.2.Global GDP Growth Outlook
- 2.3.3.Global Healthcare Spending Outlook
- 2.4.COVID-19 Impact Analysis
- 2.5.Forecast Factors - Relevance and Impact
3.Value Added Insights
- 3.1.Product Adoption Analysis
- 3.2.Technology Assessment
- 3.3.Regulatory Landscape
- 3.4.Supply Chain Analysis
- 3.5.Key Deals and Mergers
- 3.6.PESTLE Analysis
- 3.7.Porter's Five Force Analysis
4.Price Analysis, 2024A
- 4.1.Key Highlights
- 4.2.Key Factors Impacting Indication Prices
- 4.3.Pricing Analysis, By Component
- 4.4.Regional Prices and Indication Preferences
5.Global AI in Oncology Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
- 5.1.Key Highlights
- 5.1.1.Market Size (US$ Bn) and Y-o-Y Growth
- 5.1.2.Absolute $ Opportunity
- 5.2.Market Size (US$ Bn) Analysis and Forecast
- 5.2.1.Historical Market Size (US$ Bn) Analysis, 2019-2023
- 5.2.2.Current Market Size (US$ Bn) Analysis and Forecast, 2024-2031
- 5.3.Global AI in Oncology Market Outlook: Component
- 5.3.1.Introduction / Key Findings
- 5.3.2.Historical Market Size (US$ Bn) Analysis, By Component, 2019-2023
- 5.3.3.Current Market Size (US$ Bn) Analysis and Forecast, By Component, 2024-2031
- 5.3.3.1.Software Solutions
- 5.3.3.2.Hardware
- 5.3.3.3.Services
- 5.4.Market Attractiveness Analysis: Component
- 5.5.Global AI in Oncology Market Outlook: Indication
- 5.5.1.Introduction / Key Findings
- 5.5.2.Historical Market Size (US$ Bn) Analysis, By Indication, 2019-2023
- 5.5.3.Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024-2031
- 5.5.3.1.Breast Cancer
- 5.5.3.2.Lung Cancer
- 5.5.3.3.Prostate Cancer
- 5.5.3.4.Colorectal Cancer
- 5.5.3.5.Brain Tumour
- 5.5.3.6.Others
- 5.6.Market Attractiveness Analysis: Indication
- 5.7.Global AI in Oncology Market Outlook: Treatment
- 5.7.1.Introduction / Key Findings
- 5.7.2.Historical Market Size (US$ Bn) Analysis, By Treatment, 2019-2023
- 5.7.3.Current Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2024-2031
- 5.7.3.1.Chemotherapy
- 5.7.3.2.Immunotherapy
- 5.7.3.3.Radiotherapy
- 5.7.3.4.Others
- 5.8.Market Attractiveness Analysis: Treatment
- 5.9.Global AI in Oncology Market Outlook: End User
- 5.9.1.Introduction / Key Findings
- 5.9.2.Historical Market Size (US$ Bn) Analysis, By End User, 2019-2023
- 5.9.3.Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024-2031
- 5.9.3.1.Hospitals
- 5.9.3.2.Biopharmaceutical Companies
- 5.9.3.3.Academic and Research Centers
- 5.9.3.4.Others
- 5.10.Market Attractiveness Analysis: End User
6.Global AI in Oncology Market Outlook: Region
- 6.1.Key Highlights
- 6.2.Historical Market Size (US$ Bn) Analysis, By Region, 2019-2023
- 6.3.Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2024-2031
- 6.3.1.North America
- 6.3.2.Europe
- 6.3.3.East Asia
- 6.3.4.South Asia and Oceania
- 6.3.5.Latin America
- 6.3.6.Middle East & Africa
- 6.4.Market Attractiveness Analysis: Region
7.North America AI in Oncology Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
- 7.1.Key Highlights
- 7.2.Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
- 7.2.1.By Country
- 7.2.2.By Component
- 7.2.3.By Indication
- 7.2.4.By Treatment
- 7.2.5.By End User
- 7.3.Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
- 7.3.1.U.S.
- 7.3.2.Canada
- 7.4.Current Market Size (US$ Bn) Analysis and Forecast, By Component, 2024-2031
- 7.4.1.Software Solutions
- 7.4.2.Hardware
- 7.4.3.Services
- 7.5.Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024-2031
- 7.5.1.Breast Cancer
- 7.5.2.Lung Cancer
- 7.5.3.Prostate Cancer
- 7.5.4.Colorectal Cancer
- 7.5.5.Brain Tumour
- 7.5.6.Others
- 7.6.Current Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2024-2031
- 7.6.1.Chemotherapy
- 7.6.2.Immunotherapy
- 7.6.3.Radiotherapy
- 7.6.4.Others
- 7.7.Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024-2031
- 7.7.1.Hospitals
- 7.7.2.Biopharmaceutical Companies
- 7.7.3.Academic and Research Centers
- 7.7.4.Others
- 7.8.Market Attractiveness Analysis
8.Europe AI in Oncology Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
- 8.1.Key Highlights
- 8.2.Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
- 8.2.1.By Country
- 8.2.2.By Component
- 8.2.3.By Indication
- 8.2.4.By Treatment
- 8.2.5.By End User
- 8.3.Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
- 8.3.1.Germany
- 8.3.2.France
- 8.3.3.U.K.
- 8.3.4.Italy
- 8.3.5.Spain
- 8.3.6.Russia
- 8.3.7.Turkiye
- 8.3.8.Rest of Europe
- 8.4.Current Market Size (US$ Bn) Analysis and Forecast, By Component, 2024-2031
- 8.4.1.Software Solutions
- 8.4.2.Hardware
- 8.4.3.Services
- 8.5.Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024-2031
- 8.5.1.Breast Cancer
- 8.5.2.Lung Cancer
- 8.5.3.Prostate Cancer
- 8.5.4.Colorectal Cancer
- 8.5.5.Brain Tumour
- 8.5.6.Others
- 8.6.Current Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2024-2031
- 8.6.1.Chemotherapy
- 8.6.2.Immunotherapy
- 8.6.3.Radiotherapy
- 8.6.4.Others
- 8.7.Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024-2031
- 8.7.1.Hospitals
- 8.7.2.Biopharmaceutical Companies
- 8.7.3.Academic and Research Centers
- 8.7.4.Others
- 8.8.Market Attractiveness Analysis
9.East Asia AI in Oncology Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
- 9.1.Key Highlights
- 9.2.Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
- 9.2.1.By Country
- 9.2.2.By Component
- 9.2.3.By Indication
- 9.2.4.By Treatment
- 9.2.5.By End User
- 9.3.Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
- 9.3.1.China
- 9.3.2.Japan
- 9.3.3.South Korea
- 9.4.Current Market Size (US$ Bn) Analysis and Forecast, By Component, 2024-2031
- 9.4.1.Software Solutions
- 9.4.2.Hardware
- 9.4.3.Services
- 9.5.Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024-2031
- 9.5.1.Breast Cancer
- 9.5.2.Lung Cancer
- 9.5.3.Prostate Cancer
- 9.5.4.Colorectal Cancer
- 9.5.5.Brain Tumour
- 9.5.6.Others
- 9.6.Current Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2024-2031
- 9.6.1.Chemotherapy
- 9.6.2.Immunotherapy
- 9.6.3.Radiotherapy
- 9.6.4.Others
- 9.7.Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024-2031
- 9.7.1.Hospitals
- 9.7.2.Biopharmaceutical Companies
- 9.7.3.Academic and Research Centers
- 9.7.4.Others
- 9.8.Market Attractiveness Analysis
10.South Asia & Oceania AI in Oncology Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
- 10.1.Key Highlights
- 10.2.Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
- 10.2.1.By Country
- 10.2.2.By Component
- 10.2.3.By Indication
- 10.2.4.By Treatment
- 10.2.5.By End User
- 10.3.Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
- 10.3.1.India
- 10.3.2.Southeast Asia
- 10.3.3.ANZ
- 10.3.4.Rest of South Asia & Oceania
- 10.4.Current Market Size (US$ Bn) Analysis and Forecast, By Component, 2024-2031
- 10.4.1.Software Solutions
- 10.4.2.Hardware
- 10.4.3.Services
- 10.5.Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024-2031
- 10.5.1.Breast Cancer
- 10.5.2.Lung Cancer
- 10.5.3.Prostate Cancer
- 10.5.4.Colorectal Cancer
- 10.5.5.Brain Tumour
- 10.5.6.Others
- 10.6.Current Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2024-2031
- 10.6.1.Chemotherapy
- 10.6.2.Immunotherapy
- 10.6.3.Radiotherapy
- 10.6.4.Others
- 10.7.Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024-2031
- 10.7.1.Hospitals
- 10.7.2.Biopharmaceutical Companies
- 10.7.3.Academic and Research Centers
- 10.7.4.Others
- 10.8.Market Attractiveness Analysis
11.Latin America AI in Oncology Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
- 11.1.Key Highlights
- 11.2.Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
- 11.2.1.By Country
- 11.2.2.By Component
- 11.2.3.By Indication
- 11.2.4.By Treatment
- 11.2.5.By End User
- 11.3.Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
- 11.3.1.Brazil
- 11.3.2.Mexico
- 11.3.3.Rest of Latin America
- 11.4.Current Market Size (US$ Bn) Analysis and Forecast, By Component, 2024-2031
- 11.4.1.Software Solutions
- 11.4.2.Hardware
- 11.4.3.Services
- 11.5.Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024-2031
- 11.5.1.Breast Cancer
- 11.5.2.Lung Cancer
- 11.5.3.Prostate Cancer
- 11.5.4.Colorectal Cancer
- 11.5.5.Brain Tumour
- 11.5.6.Others
- 11.6.Current Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2024-2031
- 11.6.1.Chemotherapy
- 11.6.2.Immunotherapy
- 11.6.3.Radiotherapy
- 11.6.4.Others
- 11.7.Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024-2031
- 11.7.1.Hospitals
- 11.7.2.Biopharmaceutical Companies
- 11.7.3.Academic and Research Centers
- 11.7.4.Others
- 11.8.Market Attractiveness Analysis
12.Middle East & Africa AI in Oncology Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
- 12.1.Key Highlights
- 12.2.Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
- 12.2.1.By Country
- 12.2.2.By Component
- 12.2.3.By Indication
- 12.2.4.By Treatment
- 12.2.5.By End User
- 12.3.Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
- 12.3.1.GCC Countries
- 12.3.2.Egypt
- 12.3.3.South Africa
- 12.3.4.Northern Africa
- 12.3.5.Rest of Middle East & Africa
- 12.4.Current Market Size (US$ Bn) Analysis and Forecast, By Component, 2024-2031
- 12.4.1.Software Solutions
- 12.4.2.Hardware
- 12.4.3.Services
- 12.5.Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024-2031
- 12.5.1.Breast Cancer
- 12.5.2.Lung Cancer
- 12.5.3.Prostate Cancer
- 12.5.4.Colorectal Cancer
- 12.5.5.Brain Tumour
- 12.5.6.Others
- 12.6.Current Market Size (US$ Bn) Analysis and Forecast, By Treatment, 2024-2031
- 12.6.1.Chemotherapy
- 12.6.2.Immunotherapy
- 12.6.3.Radiotherapy
- 12.6.4.Others
- 12.7.Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024-2031
- 12.7.1.Hospitals
- 12.7.2.Biopharmaceutical Companies
- 12.7.3.Academic and Research Centers
- 12.7.4.Others
- 12.8.Market Attractiveness Analysis
13.Competition Landscape
- 13.1.Market Share Analysis, 2024
- 13.2.Market Structure
- 13.2.1.Competition Intensity Mapping By Market
- 13.2.2.Competition Dashboard
- 13.3.Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
- 13.3.1.Azra AI
- 13.3.1.1.Overview
- 13.3.1.2.Segments and Products
- 13.3.1.3.Key Financials
- 13.3.1.4.Market Developments
- 13.3.1.5.Market Strategy
- 13.3.2.IBM
- 13.3.2.1 Overview
- 13.3.2.2.Segments and Products
- 13.3.2.3.Key Financials
- 13.3.2.4.Market Developments
- 13.3.2.5.Market Strategy
- 13.3.3.Siemens Healthcare GmbH
- 13.3.3.1.Overview
- 13.3.3.2.Segments and Products
- 13.3.3.3.Key Financials
- 13.3.3.4.Market Developments
- 13.3.3.5.Market Strategy
- 13.3.4.Intel Corporation
- 13.3.4.1.Overview
- 13.3.4.2.Segments and Products
- 13.3.4.3.Key Financials
- 13.3.4.4.Market Developments
- 13.3.4.5.Market Strategy
- 13.3.5.GE Healthcare
- 13.3.5.1.Overview
- 13.3.5.2.Segments and Products
- 13.3.5.3.Key Financials
- 13.3.5.4.Market Developments
- 13.3.5.5.Market Strategy
- 13.3.6.NVIDIA Corporation
- 13.3.6.1.Overview
- 13.3.6.2.Segments and Products
- 13.3.6.3.Key Financials
- 13.3.6.4.Market Developments
- 13.3.6.5.Market Strategy
- 13.3.7.Digital Diagnostics Inc.
- 13.3.7.1.Overview
- 13.3.7.2.Segments and Products
- 13.3.7.3.Key Financials
- 13.3.7.4.Market Developments
- 13.3.7.5.Market Strategy
- 13.3.8.ConcertAI
- 13.3.8.1.Overview
- 13.3.8.2.Segments and Products
- 13.3.8.3.Key Financials
- 13.3.8.4.Market Developments
- 13.3.8.5.Market Strategy
- 13.3.9.Median Technologies
- 13.3.9.1.Overview
- 13.3.9.2.Segments and Products
- 13.3.9.3.Key Financials
- 13.3.9.4.Market Developments
- 13.3.9.5.Market Strategy
- 13.3.10.PathAI
- 13.3.10.1.Overview
- 13.3.10.2.Segments and Products
- 13.3.10.3.Key Financials
- 13.3.10.4.Market Developments
- 13.3.10.5.Market Strategy
- 13.3.11.Berg (BPGbio Inc.)
- 13.3.11.1.Overview
- 13.3.11.2.Segments and Products
- 13.3.11.3.Key Financials
- 13.3.11.4.Market Developments
- 13.3.11.5.Market Strategy
- 13.3.12.CancerCenter.AI
- 13.3.12.1.Overview
- 13.3.12.2.Segments and Products
- 13.3.12.3.Key Financials
- 13.3.12.4.Market Developments
- 13.3.12.5.Market Strategy
- 13.3.13.iCAD
- 13.3.13.1.Overview
- 13.3.13.2.Segments and Products
- 13.3.13.3.Key Financials
- 13.3.13.4.Market Developments
- 13.3.13.5.Market Strategy
- 13.3.14.JLK Inspection
- 13.3.14.1.Overview
- 13.3.14.2.Segments and Products
- 13.3.14.3.Key Financials
- 13.3.14.4.Market Developments
- 13.3.14.5.Market Strategy
- 13.3.15.Roche Diagnostics
- 13.3.15.1.Overview
- 13.3.15.2.Segments and Products
- 13.3.15.3.Key Financials
- 13.3.15.4.Market Developments
- 13.3.15.5.Market Strategy
- 13.3.16.Zebra Medical Vision
- 13.3.16.1.Overview
- 13.3.16.2.Segments and Products
- 13.3.16.3.Key Financials
- 13.3.16.4.Market Developments
- 13.3.16.5.Market Strategy
- 13.3.17.Illumina Inc.
- 13.3.17.1.Overview
- 13.3.17.2.Segments and Products
- 13.3.17.3.Key Financials
- 13.3.17.4.Market Developments
- 13.3.17.5.Market Strategy
- 13.3.18.Envisionit DeepAI Ltd
- 13.3.18.1.Overview
- 13.3.18.2.Segments and Products
- 13.3.18.3.Key Financials
- 13.3.18.4.Market Developments
- 13.3.18.5.Market Strategy
- 13.3.1.Azra AI
14.Appendix
- 14.1.Research Methodology
- 14.2.Research Assumptions
- 14.3.Acronyms and Abbreviations
